Switch theme
Sign up to access all valuation multiples
Almirall SA is a Spain-based company engaged in development, manufacture, and selling pharmaceutical products across a range of therapeutic areas. It aims to provide treatments in areas of dermatology, respiratory, gastrointestinal, central nervous systems, and other specialties. The company operates in five segments: Sales of its own network, sales of licensees, Research and developments, Sales of Therapeutic dermatological products in the U.S., and Corporate management. The medical dermatology business in the Europe is the key driver of the company’s operation. Other than Europe, the company also operates in the Americas, Asia, Africa, and Oceania through subsidiaries.
1943
576
LTM Revenue $1.2B
LTM EBITDA $250M
$2.7B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Almirall has a last 12-month revenue (LTM) of $1.2B and a last 12-month EBITDA of $250M.
In the most recent fiscal year, Almirall achieved revenue of $1.2B and an EBITDA of $205M.
Almirall expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Almirall valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $1.2B | XXX | $1.2B | XXX | XXX | XXX |
| Gross Profit | $795M | XXX | $905M | XXX | XXX | XXX |
| Gross Margin | 65% | XXX | 78% | XXX | XXX | XXX |
| EBITDA | $250M | XXX | $205M | XXX | XXX | XXX |
| EBITDA Margin | 20% | XXX | 18% | XXX | XXX | XXX |
| EBIT | $79.8M | XXX | $55.1M | XXX | XXX | XXX |
| EBIT Margin | 6% | XXX | 5% | XXX | XXX | XXX |
| Net Profit | $36.4M | XXX | $12.0M | XXX | XXX | XXX |
| Net Margin | 3% | XXX | 1% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of July 2, 2025, Almirall's stock price is EUR 11 (or $13).
Almirall has current market cap of EUR 2.3B (or $2.7B), and EV of EUR 2.3B (or $2.7B).
See Almirall trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $2.7B | $2.7B | XXX | XXX | XXX | XXX | $0.21 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of July 2, 2025, Almirall has market cap of $2.7B and EV of $2.7B.
Almirall's trades at 2.3x EV/Revenue multiple, and 12.9x EV/EBITDA.
Equity research analysts estimate Almirall's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Almirall has a P/E ratio of 74.0x.
See valuation multiples for Almirall and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $2.7B | XXX | $2.7B | XXX | XXX | XXX |
| EV (current) | $2.7B | XXX | $2.7B | XXX | XXX | XXX |
| EV/Revenue | 2.2x | XXX | 2.3x | XXX | XXX | XXX |
| EV/EBITDA | 10.6x | XXX | 12.9x | XXX | XXX | XXX |
| EV/EBIT | 33.3x | XXX | 48.1x | XXX | XXX | XXX |
| EV/Gross Profit | 3.3x | XXX | n/a | XXX | XXX | XXX |
| P/E | 74.0x | XXX | 225.0x | XXX | XXX | XXX |
| EV/FCF | 33.4x | XXX | -3388.7x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialAlmirall's last 12 month revenue growth is 12%
Almirall's revenue per employee in the last FY averaged $2.0M, while opex per employee averaged $1.5M for the same period.
Almirall's rule of 40 is 25% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Almirall's rule of X is 50% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Almirall and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 12% | XXX | 12% | XXX | XXX | XXX |
| EBITDA Margin | 20% | XXX | 18% | XXX | XXX | XXX |
| EBITDA Growth | 20% | XXX | 42% | XXX | XXX | XXX |
| Rule of 40 | 25% | XXX | 30% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 50% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $2.0M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $1.5M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 10% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 8% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 73% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Almirall acquired XXX companies to date.
Last acquisition by Almirall was XXXXXXXX, XXXXX XXXXX XXXXXX . Almirall acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Almirall founded? | Almirall was founded in 1943. |
| Where is Almirall headquartered? | Almirall is headquartered in Spain. |
| How many employees does Almirall have? | As of today, Almirall has 576 employees. |
| Who is the CEO of Almirall? | Almirall's CEO is Mr. Carlos Gallardo Pique. |
| Is Almirall publicy listed? | Yes, Almirall is a public company listed on MAD. |
| What is the stock symbol of Almirall? | Almirall trades under ALM ticker. |
| When did Almirall go public? | Almirall went public in 2007. |
| Who are competitors of Almirall? | Similar companies to Almirall include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Almirall? | Almirall's current market cap is $2.7B |
| What is the current revenue of Almirall? | Almirall's last 12 months revenue is $1.2B. |
| What is the current revenue growth of Almirall? | Almirall revenue growth (NTM/LTM) is 12%. |
| What is the current EV/Revenue multiple of Almirall? | Current revenue multiple of Almirall is 2.2x. |
| Is Almirall profitable? | Yes, Almirall is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Almirall? | Almirall's last 12 months EBITDA is $250M. |
| What is Almirall's EBITDA margin? | Almirall's last 12 months EBITDA margin is 20%. |
| What is the current EV/EBITDA multiple of Almirall? | Current EBITDA multiple of Almirall is 10.6x. |
| What is the current FCF of Almirall? | Almirall's last 12 months FCF is $79.3M. |
| What is Almirall's FCF margin? | Almirall's last 12 months FCF margin is 6%. |
| What is the current EV/FCF multiple of Almirall? | Current FCF multiple of Almirall is 33.4x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
